NouvNeu004: Recently received I-III all-stage IND approval from the NMPA, making it the world's first cell therapy product for Multiple System Atrophy (MSA) and iRegene's third self-developed product ...
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing ...
Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
Additional funding of $20 million accelerates commercialization of Trailhead's iPSC-derived human cell and media products. BEACHWOOD, Ohio and CAMBRIDGE, ...
San Diego, CA, 12 January, 2026: iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and ...
13d
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Detailed price information for Creative Medical Technology Holdings Inc (CELZ-Q) from The Globe and Mail including charting and trades.
Remains on track to name a development candidate for a novel first-in-class neurology program targeting demyelinating diseases in 2026Progresses discovery work on a best-in-class cell therapeutic ...
Novoron Bioscience, a San Diego-based biotechnology company developing therapies for neurodegenerative diseases and neurological injury, has received a $2.5 million Small Business Innovation Research ...
SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results